Lokivetmab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | interleukin 31 (IL-31) |
| Clinical data | |
| Trade names | Cytopoint |
| Routes of administration | subcutaneous injection |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs.[1] It acts against interleukin 31 (IL-31),[2] which is a cytokine involved in causing itchiness (pruritus).[2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.[3]
The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016,[3] and it was approved by the European Medicines Agency in 2017.[4] Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.[4]
References
- ↑ "Zoetis earns license for Cytopoint skin therapy". Veterinary Practice News. 4 January 2017. Retrieved 2018-07-06.
- 1 2 Marsella R, De Benedetto A (July 2017). "Atopic Dermatitis in Animals and People: An Update and Comparative Review". Veterinary Sciences. 4 (3): 37. doi:10.3390/vetsci4030037. PMC 5644664. PMID 29056696.
- 1 2 McKay L (13 July 2017). "Making a difference for dogs with atopic dermatitis: When to use Apoquel and when to use Cytopoint". dvm360.com. Retrieved 2018-07-07.
- 1 2 "First antibody therapy in veterinary medicine launched for dogs in the UK". The Veterinary Record. 181 (1): 6–7. July 2017. doi:10.1136/vr.j3147. PMID 28667135. S2CID 20166012.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.